MD Conference Express ESC 2012 - (Page 1)

Peer-Reviewed CARDIOLOGY Clinical Trial Highlights THE OFFICIAL PEER-REVIEWED HIGHLIGHTS FROM THE Translational Research 25 - 29 August, 2012 Munich, Germany Therapeutic Updates TAVI: 10 Years after the First Case The first human transcatheter aortic valve implantation (TAVI) was performed in 2002. Since then, TAVI has been evaluated as an alternative to surgical aortic valve replacement and medical treatment in several clinical trials. Steven Windecker, MD, Bern University Hospital, Bern, Switzerland, reviewed the evidence from these trials. See page 9. Distribution of this independent report is supported by ALSO IN THIS ISSUE • 2012 ESC Guidelines Overview • Clinical Trial Highlights – The Science Behind Cardiology • New Treatment Approaches for Hypertension  http://www.mdconferencexpress.com http://www.escardio.org

Table of Contents for the Digital Edition of MD Conference Express ESC 2012

MD Conference Express ESC 2012
Contents
ESC 2012 Clinical Practice Guidelines
TAVI: 10 Years After the First Case
PARAMOUNT Trial Results
TRILOGY ACS Outcomes
Results from the ALTITUDE Trial
Results of the WOEST Trial
Results from the Aldo-DHF Trial
FAME 2 Results
Results from the IABP-SHOCK II Trial
STEMI Mortality Decreases in France While Some Key Risk Factors Increase
Results from the PURE Study
PURE: Treatment and Control of Hypertension
Genetic Determinants of Variability in Dabigatran Exposure
The RE-LY AF Registry
TRA 2°P-TIMI 50 Results
Rivaroxaban of Benefit in STEMI: ATLAS ACS 2-TIMI 51
Ivabradine Effect on Recurrent Hospitalization for HF
CLARIFY: Similar 1-Year Outcomes for Men and Women with Stable CAD
HPS2-THRIVE Study Results
PRoFESS Study Results
Outcomes from the CARDia Trial
Hypertension
Atrial Fibrillation
Heart Failure

MD Conference Express ESC 2012

https://www.nxtbook.com/nxtbooks/md_conference_express/esc2012
https://www.nxtbookmedia.com